Global Information
회사소개 | 문의 | 비교리스트

뉴트리지노믹스 시장 : 성장, 동향, COVID-19의 영향 및 예측(2021-2026년)

Nutrigenomics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2022년 01월 상품코드 1005827
페이지 정보 영문 배송안내 2-3일 (영업일 기준)
US $ 4,750 ₩ 6,256,000 PDF & Excel (Single User License)
US $ 5,250 ₩ 6,914,000 PDF & Excel (Team License: Up to 7 Users)
US $ 6,500 ₩ 8,561,000 PDF & Excel (Site License)
US $ 8,750 ₩ 11,524,000 PDF & Excel (Corporate License)

뉴트리지노믹스 시장 : 성장, 동향, COVID-19의 영향 및 예측(2021-2026년) Nutrigenomics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
발행일 : 2022년 01월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 뉴트리지노믹스 시장 규모는 예측기간 중 15.5%의 CAGR로 확대될 것으로 예측됩니다.

COVID-19 팬데믹은 의료기기, 의약품, 바이오테크놀러지 산업을 포함한 대부분의 부문에 잠재적인 경제적 영향을 미쳤습니다. 각국의 정부는 COVID-19의 위협에 대응해 사회적 거리두기, 전국적인 락다운, 여행 제한, 대규모 검역 등 모든 중요한 대책을 강구하고, 이것에 의해 기업과 개인 소비에 마이너스 영향이 되었습니다. 많은 국가가 봉쇄되고, 다른 국가와의 무역을 정지하고, 세계 주요 기업의 시가총액이 감소하고, 산업 생산이나 기타 사업이 감소했습니다.

또한 COVID-19는 시장에 영향을 미쳤습니다. 세계적으로 영양 습관이나 건강식품, 식품 알레르기, 맞춤형 건강에 대한 기호 등에 관한 인식 확산에 의해 사람들은 약물유전학 시험에 참여하게 되었으며, 시장 성장을 나타내고 있습니다.

시장 성장을 추진하고 있는 요인에는 비만 유병률 상승과 운동선수 사이의 맞춤형 다이어트 증가 경향과 타겟 인구 사이에서의 의식 향상 등이 있습니다.

또한 세계적으로 암 발생률 상승이 시장 성장을 추진하고 있습니다. 예를 들어 Globocan Database에 의하면 2020년에는 약 19,292,789명의 새로운 암증례가 있고, 9,9581,33명이 암에 의해 사망했습니다. 또한 향후에는 새로운 암증례수가 2018년 1,810만명에서 2040년에는 2,940만명으로 증가할 것으로 보입니다. 또한 개인 레벨에서의 적절한 식사 영양은 암으로의 감수성을 저하시켜 시장 전체를 지지할 것으로 예측됩니다.

세계의 뉴트리지노믹스(Nutrigenomics) 시장에 대해 조사했으며, 시장 개요와 함께 용도별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공합니다.


제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 성장 촉진요인
    • 비만 유병률 증가
    • 맞춤형 다이어트 인기 상승
    • 암 예방과 치료를 위한 집중적 연구
  • 시장 성장 억제요인
    • 규제 당국의 승인 결여
    • 뉴트리지노믹스 연구 지원을 위한 증명된 결과 결여
  • Porter's Five Forces 분석

제5장 시장 세분화

  • 용도별
    • 심혈관질환
    • 비만
    • 암조사
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동과 아프리카
    • 남미

제6장 경쟁 상황

  • 기업 개요
    • DSM
    • BASF SE
    • Danone
    • Genova Diagnostics
    • Cell-Logic
    • Metagenics, Inc.
    • GeneSmart
    • GX Sciences Inc
    • Nutrigenomix Inc.
    • Unilever Group
    • Xcode Life Sciences Private Limited.
    • Holistic Heal
    • GX Sciences Inc.
    • Genelex
    • OmeCare Inc

제7장 시장 기회와 동향

KSM 21.05.28

The nutrigenomics market is expected to witness a CAGR of 15.5% during the forecast period.

The COVID-19 pandemic had a potential economic impact and implications on most sectors, including the medical devices, pharmaceutical, and biotech industries. Worldwide governments responded to the threat of COVID-19 with all the essential measures, such as social distancing, nationwide lockdown, travel restrictions, and large-scale quarantines, anticipated to impact the businesses and consumer spending negatively. Many countries had been in lockdown and have suspended the trades with other countries, leading to declining market capitalizations of major companies, worldwide, along with a decline in industrial production and other businesses.​

Moreover, COVID-19 showed an impact on the market. Globally, rising awareness regarding nutrition habits and healthy food, food allergies, personalized and preference for personalized health, among other factors, has brought people to go for pharmacogenetics testing and has shown growth in the market.

Some of the factors driving the market growth include increasing awareness among the target population, the rising prevalence of obesity, and the growing trend of personalized diet among athletes.

Furthermore, globally, there is an increasing incidence of cancer, which is driving the market growth. For instance, according to the Globocan Database, in 2020, around 19,292,789 new cancer cases and 9,9581,33 deaths took place due to cancer. Moreover, it is estimated that the number of new cancer cases may grow from 18.1 million to 29.4 million, between 2018 and 2040. Furthermore, proper diet nutrition on an individual level may reduce the susceptibility to cancer, thus, boosting the overall market.

According to the World Heart Federation 2018, coronary heart disease was the leading cause of death, worldwide. An estimated 3.8 million men and 3.4 million women die each year from coronary heart disease. In addition, 80% of the deaths occur in low- and middle-income countries. Coronary artery disease (CAD) is the number one cause of cardiovascular morbidity and mortality.

Additionally, cardiovascular diseases are found as most prevalent across the world, and they are the leading causes of death. As per the 2020 updates of WHO, ischemic heart disease, responsible for 16% of the world's total deaths. Since 2000, the largest increase in deaths has been for ischemic heart disease, rising by more than 2 million to 8.9 million deaths in 2019.

Furthermore, market players adopting various strategies, such as product launches, collaborations, acquisitions, mergers, and expansions, to increase market share. For instance, in April 2019, Nutrigenomix Inc. launched a genetic test for vegetarians and vegans with plant-based personalized nutrition.

As nutrigenomics helps understand the genetic role in health and diseases, providing better therapeutic intervention helps in diagnosing the diseases. The rising importance of nutrition among the population and several advantages such as a focus on disease prevention rather than disease management and impeding the sign aging will result in propelling the nutrigenomics market. However, the lack of regulatory approvals in the field of nutrigenomics may hamper the market.

Key Market Trends

Based on Application, Obesity in Nutrigenomics Market is Expected to Witness a Healthy Growth in Future

Globally, obesity is a major health concern, worldwide, which can lead to various diseases, such as cardiovascular, type 2 diabetes, metabolic syndrome, and sometimes cancer.

According to a research article by Ahmed M. Abbas et al., published in Obesity Medicine Journal September 2020, globally, the rate of obesity was increased during this COVID-19 epidemic 2020. Moreover, obesity is dangerous in COVID-19 patients as it is associated with other co-morbidities that may affect the prognosis of COVID-19 patients.

Additionally, the high burden of obesity, worldwide, results in high demand for treatment, thus, propelling the nutrigenomics market. For instance, according to a research article by Rujuta Sachin Hadaye et al., published in the Indian Journal of Community Medicine September 2020, in India, the prevalence of obesity was 42.01%, and that of normal-weight obesity (NWO) was 16.1%. A high protein diet, sex, heavy physical activity, and alcohol intake were significantly associated with obesity.

According to the World Health Organization (WHO), estimated that around 57.8% of adults worldwide are expected to be classified as obese by 2030.

Nutrigenomics helps in understanding the population on an individual gene level. According to the genes, a proper nutrition diet is given, which further results in decreased obesity. This novel approach of nutrigenomics helps in the effective prevention and treatment of these diseases and is the key driving factor propelling the segment growth. Hence, from the factors mentioned above, the segment is estimated to witness significant growth over the forecasted period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

Some factors driving the North American nutrigenomics market are introducing and developing direct-to-consumer nutrigenomics kits and increasing intake of specialized food and diet. Moreover, the rising prevalence of obesity population with the presence of an aging population, increasing healthcare expenditure, and the presence of well-established healthcare infrastructure.

As per World Obesity Federation, obesity-related conditions seem to worsen the effect of COVID-19 patients. Moreover, the Centers for Disease Control and Prevention (CDC) reported that people with heart disease and diabetes are at higher risk of COVID-19 complications.

As per the Centers for Disease Control and Prevention (CDC), the prevalence of obesity among United States adults was 42.4% in 2017-2018. Additionally, the prevalence of obesity was 40.0% among younger adults aged 20-39 years, 44.8% among middle-aged adults aged 40-59 years, and 42.8% among older adults aged 60 years and above.

As per the Heart and Stroke Foundation 2019 report, each year, more than 62,000 people get attack with stroke in Canada, and that number is expected to rise. More than 405,000 people in the country live with the effects of stroke. Furthermore, the number of people who die in the hospital within 90 days is 7.6 times higher for people with heart valve disease and heart failure than heart valve disease alone. Thus, nutrigenomics helps understand the genetic role in health and cardiovascular diseases by providing better therapeutic intervention that helps diagnose and manage the disease, which is likely to boost the market growth in the future.

Competitive Landscape

The nutrigenomics market is fragmented competitive and consists of several major players. The market players with more funds for R&D have established their position in the market. Moreover, several companies are shifting their focus on the development of tailor-made food to match a particular gene profile, such as strengthening the weak immune system and decreasing the intake of cholesterol compounds. Some market players are DSM, BASF SE, Danone, Genova Diagnostics, Cell-Logic, Metagenics Inc, and GeneSmart, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Obesity
    • 4.2.2 Increasing Popularity for Personalised Diet
    • 4.2.3 Intense Research for Cancer Prevention and Cure
  • 4.3 Market Restraints
    • 4.3.1 Lack of Regulatory Approvals
    • 4.3.2 Lack of Proven Results for Nutrigenomics Study Support
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers/Consumers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Application
    • 5.1.1 Cardiovascular Diseases
    • 5.1.2 Obesity
    • 5.1.3 Cancer Research
    • 5.1.4 Other Applications
  • 5.2 By Geography
    • 5.2.1 North America
      • United States
      • Canada
      • Mexico
    • 5.2.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.2.3 Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia Pacific
    • 5.2.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.2.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 DSM
    • 6.1.2 BASF SE
    • 6.1.3 Danone
    • 6.1.4 Genova Diagnostics
    • 6.1.5 Cell-Logic
    • 6.1.6 Metagenics Inc.
    • 6.1.7 GeneSmart
    • 6.1.8 GX Sciences Inc.
    • 6.1.9 Nutrigenomix Inc.
    • 6.1.10 Unilever Group
    • 6.1.11 Xcode Life Sciences Private Limited.
    • 6.1.12 Holistic Heal
    • 6.1.13 GX Sciences Inc.
    • 6.1.14 Genelex
    • 6.1.15 OmeCare Inc.


Back to Top
전화 문의